What’s New With Cannabis Stocks for the Week Ending 12/03/21

Navigate the fast-moving cannabis sector with 420 Investor, a premium service that sends real-time alerts and explanations of the news below and much more.

Summary 

• BDSA data suggested cannabis sales declines over the past few months abated in October.
• 420 Investor model portfolios have returned -15.5% to 25.3% year-to-date, while the Global Cannabis Stock Index has lost 21.7%.

Review

Most states showed stabilizing cannabis sales during October after weakness in the prior few months, according to BDSA.

During the week, I shared these insights with subscribers at 420 Investor:

• Model Portfolio Composition 11/26/21
• Cannabis Sub-Sector Review – 11/26/21
• Preview of Harborside Q3 Financials

Here are some of this week’s highlights for 420 Investor Focus List names:

• CCHWF became the first American cannabis company added to the MSCI Canada Small Cap Index.
• CURLF expanded its BNOBLE brand to New York.
• FFLWD reverse split 1:10 ahead of its upcoming NASDAQ listing. It reached 360K members of its Spark Perks loyalty program.
• GNLN completed its acquisition of dry herb vaporizer company DaVinci, which is on track for 2021 revenue of $12 million with a gross margin of 60%.
• HBORF Q3 revenue was slightly behind expectations at $17.4 million, with adjusted EBITDA of $1.5 million. The company announced the pending merger with Urbn Leaf and Loudpack, with the deal supported by $77.3 million in debt financing. It also is offering up to $10 million in units at C$0.79, with each unit consisting of a share and a warrant at C$0.79.
• SHWZ borrowed $95 million at 13% and announced an acquisition to enter New Mexico.
• TCNNF issued its first Environmental, Social, and Governance (ESG) Report. It opened its 110th Florida medical dispensary.
• TLRY launched oral strips.
• VRNOF opened its 13th Pennsylvania medical dispensary.

Market Performance

The Global Cannabis Stock Index plunged again to a new 52-week closing low on Friday, decreasing 10.2% during the week to 34.74:

The index, which lost 34.1% in 2019 and lost 54.9% in 2018 after gaining 91.8% in 2017 and 88.8% in 2016, was up 5.2% in 2020. It has lost 21.7% in 2021 thus far. It currently includes 42 stocks and ended 2020 at 44.39:

Model Portfolios

420 Investor offers three model portfolios for subscribers, including two that are long-term focused and fully invested with a goal of beating the Global Cannabis Stock Index, 420 Opportunity and 420 Quality. 420 Opportunity ended the week valued at $98,848, down 11.3%. The model portfolio, down 6.2% in 2021, gained 35.6% in 2020 and has increased 97.8% since April 2014 despite the large loss in the index since then. 420 Quality ended the week at $136,502, down 11.5% for the week, and is now down 15.5% in 2021 after gaining 42.8% in 2020. The model was launched in March 2017 targeting long-term investors seeking to invest in leading cannabis stocks with low portfolio turnover and has gained 173.0% since inception compared to the 57.0% decline in the index since then. Flying High, which is focused on swing trades, ended the week valued at $316,165, down 10.3%. The model portfolio gained 52.7% in 2020 and is up 25.3% in 2021, and the return since inception in late 2013 has been 3162%.

Outlook

After a strong rally to begin 2019, the cannabis sector experienced a sharp decline over the next year to unprecedented levels due to several negative developments, including the CannTrust fraud, the surprise termination of Bruce Linton as CEO of Canopy Growth, a disappointing roll-out of legalization in Canada, regulatory confusion in the U.S. regarding CBD and a slow roll-out of legalization in California, the vaping crisis and then financial turmoil and market disruptions due to the COVID-19 pandemic. The sector saw capital available to fund expansion dry up, a situation that continues to leave companies operating with negative cash flow severely challenged, as the availability is limited to stronger operators.

Cannabis stocks overreacted and put in a bottom in March 2020, and benefited from a perception that the industry offers strong growth prospects, something that wasn’t clear then. A big change was that the pandemic caused many regulators to permit previously prohibited types of retail activities, like curbside pickup and delivery. The legal market rapidly capitalized on becoming even more convenient than the illicit market, with the ability to order online. States and municipalities moved to broaden adult-use and medical access. Access to capital improved dramatically, and the leading companies began generating large and rapidly growing revenue and profits.

The strong finish to 2020 continued into 2021 after the Democrats took control of the Senate in early January, but the stocks got way ahead of themselves and have been consolidating since then. In addition to concerns that federal legalization will take a longer time than many have expected, there have been some tough comparisons to year-ago sales levels. Additionally, while several institutions embraced the sector early in the year, there has been a lull in additional interest.

There are several potential catalysts ahead, including the FDA (or Congress) providing clarity on CBD regulation, progress in the Canadian legalization that commenced in October 2018 and that is beginning to include a broader set of products and the continued growth in German and Israeli MMJ and other international markets that have been slow to develop. The adult-use implementations in California and Massachusetts for adult-use were slow to roll out but are beginning to show great improvement. Michigan and Illinois legalized for adult-use at the end of 2019, and these markets are showing strong growth that could encourage other states to legalize. Voters in Arizona, Montana, South Dakota and New Jersey all approved adult-use legalization in November, and Connecticut, New Mexico, New York and Virginia have enacted legalization through the legislative process in 2021.

The big themes ahead are likely to be continued cross-industry investment into the sector and more consolidation in Canada and in the U.S., potential federal regulatory reform (SAFE Banking Act and other more comprehensive legislation, which could eliminate 280E taxation and enable trading on higher exchanges for MSOs as well as the broad usage of credit cards for cannabis purchases), steps to enable cannabis research, the roll out of MMJ in Germany, Mexico and in Australia as well as continued advances in South America and potential adult-use legalization in Germany, Israel and Mexico, new legal cannabis implementations in AZ, MT, NJ and SD, and MMJ implementations in AL, WV and VA, possible legalization via the legislatures in DE, FL, MD, MN, NH, PA and RI and implementation of the CT, NM, NY and VT commercial programs in 2022 and VA in 2024. It is interesting to see both parties embracing cannabis legalization legislation at the federal level, including the Republican bill, States Reform Act, and the Democrat bill, Cannabis Administration and Opportunity Act.

After bottoming in March 2020, the cannabis sector has been in a new bull market. Many companies are generating substantial revenue and some even a profit, and liquidity is much better. The sector has transitioned away from many legacy penny stocks that had never proven that they had viable businesses towards better capitalized companies, many of which have strong management teams and substantial businesses. The investor base has also transitioned, becoming increasingly more institutional.

Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email